Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03626701 · ClinicalTrials.gov registry record · NA
RES® Prepared With RECELL® Compared to Standard of Care Dressings of Partial-thickness Burns in Ages 1-16 Years
A NA study, sponsored by Avita Medical.
- Terminated
- Registry status
- NA
- Development phase
- 19
- Enrollment target
NCT03626701: Clinical Trial NA study, sponsored by Avita Medical.
NCT03626701 is a NA study that was terminated before completion, run by Avita Medical. The registered enrollment target is 19 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03626701, a NA study, was terminated before completion, sponsored by Avita Medical.
- TERMINATED
- Registry status
- NA
- Development phase
- 19 participants
- Enrollment target
Study Summary
A prospective, parallel-arm, randomized (1:1) multicenter trial to demonstrate that RECELL treatment of partial-thickness burn injuries, can safely and effectively increase the incidence of Day 10 healing compared with a standardized wound dressing.
Primary Outcome
Day 10 healing will be evaluated by an observer blinded to treatment allocation with confirmation at Day 28
Interventions
- DEVICE RES (Regenerative Epidermal Suspension) prepared using the RECELL® Autologous Cell Harvesting Device
- COMBINATION_PRODUCT Mepilex® Ag Wound Dressing
- PROCEDURE Conventional autografting (only when indicated)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2020-03-03 |
| Est. Completion | 2022-06-03 |
| Phase | NA |
Why NCT03626701 stopped before completion
NCT03626701 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 3 interventions - of which RES (Regenerative Epidermal Suspension) prepared using the RECELL® Autologous Cell Harvesting Device is the first listed.
NCT03626701 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03626701 about?
NCT03626701 is a clinical study titled "RES® Prepared With RECELL® Compared to Standard of Care Dressings of Partial-thickness Burns in Ages 1-16 Years". A prospective, parallel-arm, randomized (1:1) multicenter trial to demonstrate that RECELL treatment of partial-thickness burn injuries, can safely and effectively increase the incidence of Day 10 healing compared with a standardized wound dressing.
What is the current status of trial NCT03626701?
This trial is currently terminated. It is a NA study. The enrollment target is 19 participants. The study started on 2020-03-03. Estimated completion is 2022-06-03.
What interventions are being tested in trial NCT03626701?
The interventions under investigation include: RES (Regenerative Epidermal Suspension) prepared using the RECELL® Autologous Cell Harvesting Device (DEVICE), Mepilex® Ag Wound Dressing (COMBINATION_PRODUCT), Conventional autografting (only when indicated) (PROCEDURE).
Who is sponsoring clinical trial NCT03626701?
This trial is sponsored by Avita Medical, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03626701's enrollment target sits among peer trials
19 1861st of 2000 higher than 138 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI